Results of a support programme for
treatment of overweight and obese
patients with orlistat

K. Kobbevik¹, U. Gisletun¹, F. Hansson² and S. Tonstad³

¹Roche Norge AS, Oslo, Norway ²Planteringsvej 11, Furulund, Sweden ³Department of Preventive Cardiology, Ullevål
University Hospital, Oslo, Norway

Abstract

Background: Overweight and obesity are reaching epidemic proportions, and a variety of therapeutic
countermeasures is needed. This article describes a support programme for orlistat.

Methods: Physicians who prescribed orlistat could refer their patients to a support programme provided by
the manufacturer. A clinical nutritionist evaluated the patient’s diet and gave advice and motivational support
during approximately seven telephone consultations a year.

Design: A cohort study.

Results: Of 3526 patients (81.5% women and 18.5% men) whose first contact with the nutritionist was
recorded between April 2001 and July 2004, 3023 had at least one follow-up consultation. The mean initial
body mass index (BMI) was 33.7 (SD 9.0). Of men and women, 90% and 80%, respectively, met the
Norwegian Pharmaceutical Product Compendium criteria for orlistat. The remaining patients had a BMI
that was too low or no reported risk factors. Of the 2456 patients who reported their weight at two or more
consultations, 70% achieved a ≥5% weight loss. Patients who took part in the programme for 4.5 months or
more, and reported their weight at two or more consultations (n = 1891, 62.5%), had a mean weight reduction
of 9.1% (95% confidence interval 7.8 to 10.4%) of the initial weight.

Conclusion: The combination of telephone advice provided by a clinical nutritionist and orlistat had a
clinically significant effect among over two-thirds of patients who reported their weight. Use of orlistat largely
followed medical recommendations with regard to the target population.

Keywords: cardiovascular risk factors; dietary therapy; nutritionist, obesity; orlistat; overweight; support
programme

Received: 3 Jun. 2005; Revised 22 Jul. 2005; Accepted: 3 Aug. 2005

Introduction

Body weight is increasing in all age groups of the
Norwegian population (1). This increase in weight necessitates preventive and therapeutic countermea-
sures at several levels, including societal and indi-
vidual ones (1).

A relatively moderate loss of weight, i.e. 5–10%
of the original weight, may result in improved health and lower morbidity even if the body weight
does not reach the normal level. There is widespread agreement that this reduction in weight should be
the treatment target because it provides most of the health benefits, including improved lipids, reduced
blood pressure, reduced risk of developing type 2 diabetes, and lower fasting blood glucose in those
who have already developed type 2 diabetes (1–3).

The dietary habits of overweight and obese
patients may be modified by nutritionist-based advice, and an extensive body of experience has
underscored that follow-up during the weight-reduction phase increases the chances of success
(4–6). Obesity medication may effectively supplement diet and lifestyle changes. Orlistat is a lipase
inhibitor acting locally in the small intestine and reducing the uptake of fat from the diet by about
30% (3, 7). The medication has been approved for
treatment of obese individuals with a body mass
index (BMI) ≥30 or those overweight individuals
with a BMI ≥28 with other additional risk factors.
Adverse effects are mainly related to inhibition of
fat absorption and subsequent gastrointestinal
symptoms if the fat intake is too high. One year
after launching orlistat in Norway in March 2000, the manufacturer (Roche) introduced a follow-up programme for patients given orlistat by their physicians. The main aims of this study were to see whether patients using orlistat in clinical practice outside a controlled trial met the recommended medical criteria for the use of the medication and whether these patients achieved weight loss. The length of adherence to the programme was also examined.

**Methods**

Patients in this study who received a prescription for orlistat were offered a referral card for free follow-up by a clinical nutritionist employed by the manufacturer. The referral card was issued by the doctor, at the pharmacist or printed out from the Internet (www.lettereliv.no). This card provided information about the service and an opportunity to indicate a suitable time when the patient could be contacted. The cards that were received were followed up by written information stating that a nutritionist would telephone within 2 weeks. If the nutritionist failed to make contact with the patient, at least four new attempts were made. If contact had still not been made, the nutritionist sent a letter encouraging the patient to return an enclosed card with information about a new possible time for making contact. The follow-up started with the first telephone contact. This consultation was estimated to last for about 20 min. After this, six follow-up consultations were planned in the course of 1 year. The follow-up consultations were planned in the course of 1 year. The follow-up consultations were estimated to last for about 10 min. Further consultations were offered for as long as the patient was taking orlistat. The service was available on weekdays from 09.00 to 19.00 h. The patients were also able to call the nutritionist at a free telephone number between the agreed consultations. Patients could stop the programme at any time they chose.

Dietary advice was given according to the patient-centred clinical method (8). The nutritionist treated the patient as an equal, taking the patient’s thoughts, feelings and expectations into account. During the first telephone consultation, the patient was asked about age, height, weight at the start of treatment, earlier attempts to lose weight, present weight, target of treatment, date of starting to take orlistat, number of capsules taken per day, possible side-effects of using orlistat, physical activity, and whether the patient had other diseases or complications of overweight or obesity such as type 2 diabetes, high cholesterol or high blood pressure (only after November 2002). All data were self-reported. The patient’s diet was evaluated using the diet history method (9). If the nutritionist and/or the patient considered that the diet history did not provide an adequate picture of the diet, the patient was asked to perform a 4 day written record of the diet using kitchen scales (9).

After discussing the patient’s dietary habits and lifestyle, the nutritionist and the patient agreed on concrete targets regarding diet, physical activity and/or weight. The nutritionist helped the patient to agree on realistic targets for both the size of the weight reduction and the changes in diet and exercise habits. As well as personal advice via the telephone, the patient was given written information (Table 1) including recommendations for diet and physical activity, recipes and ideas based on the recommendations from the Nutrition Department of the Directorate for Health and Social Affairs (10). At each follow-up consultation the patient was asked about his or her weight, diet, exercise and possible side-effects of orlistat, and the nutritionist based subsequent advice on her evaluation of the weight and dietary changes, and exercise habits. The evaluation of the diet was done either by using a diet history, or by asking the patient to record all food and drinks consumed for 4 days using kitchen scales. Motivation and encouragement were also a large part of the follow-up consultations.

In general, the dietary recommendations from the Nutrition Department of the Directorate for Health and Social Affairs (10) were followed, although with a slightly higher percentage of energy from protein. The patient was advised to:

- eat three main meals and a couple of small, non-fat snacks distributed throughout the day
- be aware of the type and amount of fat
- choose low-fat meat and dairy products
- eat fatty fish at least a couple of times a week or take supplementary cod-liver or fish oil
- choose wholemeal cereal products
- eat large amounts of fruit, berries and vegetables
- reduce refined sugar.

The energy distribution in the recommended diet was <30 energy per cent ($E\%$) from fat, of which <10 $E\%$ was from saturated fat and $trans$ fat, and the remainder from unsaturated fat, 15–20 $E\%$
from protein, 50–55 E% from carbohydrates, of which as much as possible was from complex carbohydrates and as little as possible from refined carbohydrates.

The patient was also encouraged to increase his or her activity level. The targets set were carefully adjusted to suit the individual, but if possible the objective was at least 30 min of physical activity every day. When the patient had reached the desired weight and/or wanted to stop taking orlistat, it was recommended to reduce the dose gradually. This recommendation was not based on the manufacturer’s specifications or clinical trial data, but was considered by the nutritionists to be an aid to prevent sudden weight gain.

Collection of data
All data were collected on the basis of information from the patients. The data were recorded in an Access database. All the personal information was treated confidentially, and the follow-up system was approved by the Norwegian Data Inspectorate in January 2001. The information in the database was used as a case record by the nutritionist. Statistical calculations on the material in the database were carried out at regular intervals. The length of follow-up was divided into monthly or 3 monthly periods, in order to include all the available follow-up data. Month 1 was defined as 14–42 days after start of treatment, month 2 was 43–74 days after start of treatment, month 3 was 2.5–4.5 months (75–135 days) after start of treatment, month 6 was 4.5–7.5 months (136–225 days) after start of treatment, month 9 was 7.5–10.5 months (226–315 days) after start of treatment, month 12 was 10.5–13.5 months (316–405 days) after start of treatment and month 15 was 13.5–16.5 months (406–515 days) after start of treatment. To investigate whether there were differences between those who stayed in the programme for more or less than 10.5 months, the following statistical methods were used: all continuous variables were analysed using Student’s t-test and all categorical variables were analysed using the chi-squared test.

Results
From March 2001 to July 2004, nine nutritionists worked in the follow-up system. From April 2001 to 30th June 2004, 4158 referral cards requesting follow-up were received. Individuals with whom
the nutritionist failed to make contact or those who did not start taking orlistat were excluded. The remaining material consisted of 3526 patients. The mean age was 41 years (SD 14). Of these, 81.5% were women and 18.5% were men. The mean BMI at the start of treatment was 33.7 (SD 9.0). Of the patients, 66.1% had attempted to lose weight many times before, 27.6% had made some previous attempts to lose weight and 6.4% had not tried before. The mean number of orlistat capsules taken per day was 2.8 (SD 0.4).

Patients who were included after November 2002 (n = 2167, i.e. 61.5% of the whole group) were asked whether they had had additional complications of overweight or obesity such as high blood pressure, high cholesterol and type 2 diabetes. These conditions were defined according to whether the referring physician had made the diagnosis. Of these, some did not know their blood pressure (n = 87) and/or cholesterol (n = 232). Of those who were able to answer, 39.5% reported high blood pressure, 29.2% reported high cholesterol and 13.9% reported type 2 diabetes. Table 2 shows the figures in women and men.

Data were available for 3021 patients (85.7% of the group), which was sufficient to establish whether they satisfied the criteria for orlistat according to the text in the Norwegian Pharmaceutical Product Compendium. Most of these, 79.6% of the women and 89.6% of the men, satisfied the criteria. The age was ≥18 years and the BMI ≥28 in 76.1% of the women and 85.0% of the men. In 3.5% of the women and 4.6% of the men, the age was ≥18 years and the BMI ≥28, or the BMI was <30 and there was at least one concomitant risk factor such as type 2 diabetes, high total cholesterol or high blood pressure. Reasons for not satisfying these criteria were that 4.8% of the women had a BMI between 28 and 30 without risk factors; the corresponding figure in men was 1.8%. Furthermore, 10.1% of the women and 4.1% of the men had a BMI between 25 and 28, while 5.1% of the women and 3.7% of the men had a BMI below 25. Only 0.4% of the women and 0.8% of the men were under 18 years old.

The mean length of participation in the support programme was 7.2 months (SD 6.3). About 25% were followed up for 10.5 months or more. Table 3 shows those who were followed up for 10.5 months or more compared with those followed up over a shorter period. Patients who remained in the treatment programme for ≥10.5 months were older (p < 0.01) and reported a higher prevalence of risk factors including high blood pressure and high cholesterol (p < 0.01) than those who followed the programme for <10.5 months. The women who remained in the treatment programme for ≥10.5 months were also more obese than those who followed the programme for <10.5 months (p < 0.01).

Reasons for dropout in the first 15 months (Table 4) were primarily because the patients stopped taking orlistat (n = 2131, i.e. 79.9% of the reported reasons for dropout). Of these, 18.8% stopped because they thought that orlistat was too

---

Table 2. Characteristics of the patients

<table>
<thead>
<tr>
<th></th>
<th>Women n</th>
<th>Men n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number</td>
<td>2873</td>
<td>653</td>
</tr>
<tr>
<td>Age (years)</td>
<td>39.7 (13.7)</td>
<td>48.0 (13.0)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>91.4 (27.7)</td>
<td>112.7 (30.9)</td>
</tr>
<tr>
<td>BMI (kg m$^{-2}$)</td>
<td>33.3 (5.1)</td>
<td>35.1 (8.6)</td>
</tr>
<tr>
<td>Follow-up time (months)</td>
<td>7.1 (6.3)</td>
<td>7.6 (6.5)</td>
</tr>
<tr>
<td>Number of capsules of orlistat during treatment period</td>
<td>2.8 (0.4)</td>
<td>2.8 (0.5)</td>
</tr>
<tr>
<td>% with no previous attempts to lose weight</td>
<td>4.8</td>
<td>14.7</td>
</tr>
<tr>
<td>% with some previous attempts to lose weight$^a$</td>
<td>23.4</td>
<td>49.3</td>
</tr>
<tr>
<td>% with many previous attempts to lose weight$^a$</td>
<td>71.9</td>
<td>36.0</td>
</tr>
<tr>
<td>% with high blood pressure</td>
<td>32.2</td>
<td>53.5</td>
</tr>
<tr>
<td>% with high cholesterol</td>
<td>27.3</td>
<td>37.1</td>
</tr>
<tr>
<td>% with type 2 diabetes</td>
<td>13.9</td>
<td>18.2</td>
</tr>
</tbody>
</table>

Data are given as mean (SD) or as percentages.

$n$: number of data for each variable.

$^a$ “Some previous attempts” was defined as 1–9; “many previous attempts” was defined as 10 or more.
expensive, 18.7% because they had reached their weight goal, 14.7% because of lack of motivation, 12.4% because the effect of orlistat was less than desired, 8.2% because of steatorrhoea, 3.5% because of other adverse effects, 3.7% because they started other weight-loss programmes, 2.8% because they were not experiencing further weight loss, 2.1% because they became pregnant, 1.2% because they did not receive a new prescription and 13.9% for other reasons. The remaining dropouts (n = 537, i.e. 20.1% of the reported reasons for dropout) were because the patient and/or the nutritionist decided that there was no need for further follow-up (38.1%) or the patient did not respond to calls or letters from the nutritionist (61.9%).

Change in body weight in the patients who reported their weight on at least two occasions, regardless of how long they had been followed up, is shown in Table 4. The material consisted of 2456 patients (69.7% of the whole group), of whom 1998 were women and 458 were men. Patients who were excluded from this material were those who chose not to report their weight (532 women and 122 men) and/or patients where the follow-up was terminated after a single contact with the nutritionist (109 women and 31 men) and/or patients who started taking orlistat too shortly before the last date for this study (30th June 2004), so that the nutritionist had only had time for one consultation with the patient. There are several reasons for data on weight not being available at every occasion in all the patients included in this material. Some patients had not weighed themselves at the time stated, some follow-ups had been terminated before the time stated, and the nutritionist had sometimes not had time for more consultations before the data were collected from the database.

The mean weight reduction in the patients who had been followed up for at least 4.5 months, and who chose to report their weight on at least two occasions (n = 1891), was 9.1% of their original weight just before the follow-up (95% confidence interval 7.8–10.4). Of the 1992 patients who had at least 4.5 months of follow-up, 101 chose not to report weight. Of the 2456 patients who reported their weight on at least two occasions, 1720 (70.0%) achieved ≥5% weight loss and 807 (32.9%) achieved ≥10% weight loss.

Discussion

A clinically significant weight reduction was seen in patients who chose to report their weight at the start of the programme and at a minimum of one follow-up consultation. As the study is only descriptive of the use of orlistat in the context of a support programme, there was no control group who received neither support nor a prescription for orlistat (or only one of the two). As a result, the study does not prove the efficacy of orlistat. In a previously published study from general practice, in which about one-third of the patients took part in a

<table>
<thead>
<tr>
<th>Table 3. Characteristics of patients who stayed in the programme for ≥10.5 months or &lt;10.5 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Followed up</td>
</tr>
<tr>
<td>&lt;10.5 months</td>
</tr>
<tr>
<td>Number</td>
</tr>
<tr>
<td>% of female patients</td>
</tr>
<tr>
<td>% of male patients</td>
</tr>
<tr>
<td>Mean age (years)</td>
</tr>
<tr>
<td>Weight (kg) at start of treatment, women</td>
</tr>
<tr>
<td>Weight (kg) at start of treatment, men</td>
</tr>
<tr>
<td>BMI (kg m⁻²) at start of treatment, women</td>
</tr>
<tr>
<td>BMI (kg m⁻²) at start of treatment, men</td>
</tr>
<tr>
<td>% with no previous attempts to lose weight</td>
</tr>
<tr>
<td>% with some previous attempts to lose weight</td>
</tr>
<tr>
<td>% with many previous attempts to lose weight</td>
</tr>
<tr>
<td>% with high blood pressure</td>
</tr>
<tr>
<td>% with high cholesterol</td>
</tr>
<tr>
<td>% with type 2 diabetes</td>
</tr>
</tbody>
</table>

n indicates the number of data for each variable. Data are given as means (standard deviation) or as percentages.
follow-up programme similar to the present one, the mean weight reduction in 15,549 users of orlistat was 10.7% after 7.1 months (11). This effect is close to the one observed in the present programme. A series of randomized controlled clinical trials has previously shown that orlistat is more effective than placebo, and results in clinically beneficial weight reduction in patients with overweight or obesity and their complications of overweight or obesity such as type 2 diabetes and hypertension (12).

An important weakness of the present data is that they are self-reported. However, patients were their own controls. The degree of weight reduction may have been over-reported to the nutritionist who gave the advice. Patients who did not report their weight probably had poorer results than those who chose to report their weight.

The authors are not aware of previous data on whether patients who are prescribed orlistat meet medically accepted criteria for use of the medication. The majority of the patients in the current study satisfied the criteria in the Norwegian Pharmaceutical Compendium. Patients with a BMI between 25 and 30 may have had other risk factors than those that they reported.

Orlistat has been approved for treatment for 4 years, but experience has shown that many stop taking it after using it for a short period. Weight may increase again after withdrawing the medication, unless energy intake is further reduced or physical activity is increased. Patients who remained in the treatment programme for 10.5 months or more were more obese and older, and reported a higher prevalence of risk factors than those that they reported.

A change in lifestyle is an essential element in the treatment of overweight and obesity with or without medication. The mechanism of action of orlistat is directed against fat, which seems to be the most important dietary factor in the treatment of overweight and obesity (13). Changes in diet are essential to achieve weight reduction and avoid side-effects. Physicians and health personnel are often faced with challenges when giving advice to overweight and obese patients. Lack of time and knowledge about this type of therapy (14, 15) limits the amount of help that health professionals are able to give patients who are interested in weight loss. Several randomized controlled clinical trials have followed up programmes similar to the present one, the mean weight reduction in 15,549 users of orlistat was 10.7% after 7.1 months (11). This effect is close to the one observed in the present programme. A series of randomized controlled clinical trials has previously shown that orlistat is more effective than placebo, and results in clinically beneficial weight reduction in patients with overweight or obesity and their complications of overweight or obesity such as type 2 diabetes and hypertension (12).

Table 4. Weight at start of treatment and follow-up for 15 months

<table>
<thead>
<tr>
<th></th>
<th>Women</th>
<th></th>
<th>Men</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients (n) who took part in the programme</td>
<td>Patients (n) who reported their weight on at least two occasions</td>
<td>Weight (kg) (n=2)</td>
<td>BMI (kg m⁻²) (n=2)</td>
</tr>
<tr>
<td>At start of treatment</td>
<td>2873</td>
<td>1998</td>
<td>96.7 (16.7)</td>
<td>34.9 (5.4)</td>
</tr>
<tr>
<td>At month 1a</td>
<td>2585</td>
<td>1998</td>
<td>91.5 (15.8)</td>
<td>33.0 (5.0)</td>
</tr>
<tr>
<td>At month 2b</td>
<td>2390</td>
<td>1065</td>
<td>89.6 (15.7)</td>
<td>32.4 (5.0)</td>
</tr>
<tr>
<td>At month 3c</td>
<td>2104</td>
<td>1260</td>
<td>88.4 (15.6)</td>
<td>31.6 (5.0)</td>
</tr>
<tr>
<td>At month 4d</td>
<td>1605</td>
<td>1065</td>
<td>87.7 (15.1)</td>
<td>31.5 (5.1)</td>
</tr>
<tr>
<td>At month 5e</td>
<td>1088</td>
<td>713</td>
<td>87.4 (15.5)</td>
<td>31.3 (4.9)</td>
</tr>
<tr>
<td>At month 6f</td>
<td>704</td>
<td>440</td>
<td>86.7 (14.8)</td>
<td>31.3 (4.9)</td>
</tr>
<tr>
<td>At month 15g</td>
<td>394</td>
<td>279</td>
<td>86.7 (14.8)</td>
<td>31.3 (4.9)</td>
</tr>
</tbody>
</table>

Data are given as mean (SD).

a 14 - 42 days after start of treatment; b 43 - 74 days after start of treatment; c 75 - 135 days after start of treatment; d 136 - 225 days after start of treatment; e 226 - 315 days after start of treatment; f 316 - 405 days after start of treatment; g 406 - 515 days after start of treatment.
The present results show that a support programme may be a useful aid. Given regular follow-up and counselling (6, 15), a substantial majority of the patients seem to have reached the treatment target.

Acknowledgements

We would like to thank the following nutritionists who worked in the follow-up programme: Ellen-Margrethe Hovland, Janne Langehaug Antonsen, Kathrine C Haavardsholm, Merete Helgeland, Siv Tone Natland, Kristin Holvik, Marianne Tronrud and dietary adviser Mette Strøm. We would also like to thank Gunnar Hansen for care of the database, as well as all the physicians who referred patients to the programme. The study was sponsored in its entirety by Roche Norge AS.

Reported conflicts of interest: Kathrin Kobbevik and Unni Gisletun are employed by Roche. Fredrik Hansson is an independent statistical consultant who was paid by Roche for the assignment. Serena Tonstad has received honoraria from Roche, Abbott and other pharmaceutical companies for lectures.

References


Kathrin Kobbevik
Roche Norge AS
Postbox 41 Haugenstua
NO-0915 Oslo
Norway
Tel: +47 22 78 90 00
Fax: +47 22 78 90 99
E-mail: kathrin.kobbevik@broadpark.no